Totient

Totient is a privately held biotechnology company headquartered in Cambridge, Massachusetts. Employing a team of 10 individuals, the company focuses on developing innovative solutions in the field of antibody therapeutics. Totient specializes in utilizing artificial intelligence to analyze tertiary lymphoid structures (TLSs) found in tissues affected by various conditions, including autoimmunity, infections, and cancer. Through this process, they identify novel tissue-specific antigens and develop high-affinity antibodies to target these antigens. The company has already reconstructed antibodies against several established oncology targets, such as GAGE1, GAGE2A, ANXA1, C4BPB, IL14A, BIRC7, HCLS1, and GPR83, as well as undisclosed novel targets. Their approach leverages a vast database of over 50,000 patient samples, enabling them to reconstruct antibodies from individuals exhibiting exceptional immune responses. This unique methodology allows Totient to uncover and develop highly specific and effective antibody therapeutics. For further information about Totient and their groundbreaking research, please visit their website at totient.bio.